Clinical value of concurrent brain radiotherapy and targeted therapy for non-small cell lung cancer with driver gene mutations positive combined with brain metastasis
HONG Fu1 QIAN Liting2 ZHAN Bihong1 ZHANG Hongbo1
1.Department of Radiotherapy, Anhui Provincial Cancer Hospital, Anhui Province, Hefei 230031, China;
2.Department of Radiotherapy, the First Affiliated Hospital of University of Science and Technology of China Anhui Provincial Hospital, Anhui Province, Hefei 230001, China
Abstract：Objective To investigate the clinical value of concurrent brain radiotherapy (RT) and targeted therapy for non-small cell lung cancer (NSCLC) with driver gene mutations positive combined with brain metastases (BM). Methods Clinical data of 60 NSCLC patients with driver gene mutations positive combined with BM who admitted to Anhui Provincial Cancer Hospital from January 2017 to July 2020 were retrospectively analyzed. According to the treatment plan, they were divided into the concurrent therapy group (32 cases, received concurrent brain RT and targeted therapy) and the sequential treatment group (28 cases, received brain RT and targeted therapy sequentially ). Short-term efficacy and incidence of adverse reactions were compared between the two groups, and survival was assessed by Kalpan-Meier method. Results There were no statistically significant differences in the objective response rates, the incidence of adverse reactions and the median overall survival (OS) between the two groups (P > 0.05). The intracranial progression free survival (iPFS) in the concurrent therapy group was higher than that in the sequential treatment group, and the difference was statistically significant (P < 0.05). In the subgroup analysis, there were no significant differences in median OS and median iPFS between whole brain radiotherapy (WBRT), local RT, and WBRT+ local RT (P > 0.05). Conclusion The adverse reactions of NSCLC patients with driver gene mutations positive combined with BM can be controlled by concurrent brain RT and targeted therapy, and iPFS of patients can be improved.
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics [J]. CA Cancer J Clin，2019，69（1）：7-34.
[2] Levy A，Faivre-Finn C，Hasan B，et al. Young Investigators EORTC Lung Cancer Group. Diversity of brain metastases screening and management in non-small cell lung cancer in Europe：Results of the European Organisation for Research and Treatment of Cancer lung Cancer group survey [J]. Eur J Cancer，2018，93：37-46.
[3] Tan L，Wu Y，Ma X，et al. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC [J]. Pathol Oncol Res，2019， 25（2）：791-799.
[4] Zhou Y，Yu F，Zhao Y，et al. A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer：from palliative care to active player [J]. Transl Lung Cancer Res，2020，9（6）：2479-2493.
[5] Yang Z，Zhang Y，Li R，et al. Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases：a multicentre，open-label，randomized，controlled phase Ⅲ Trial [J]. Neuro Oncol，2021，23（6）：967-978.
[6] Wang C，Lu X，Lu Z，et al. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation：A meta-analysis [J]. Lung Cancer，2018，122：94-99.
[7] Martinez P，Mak RH，Oxnard GR，et al. Targed therapy as an alternative to whole-brain radiotherapy in EGFR-mutant or ALK positive non-small-cell lung cancer with brain metastases [J]. JAMA Oncol，2017，3（9）：1274-1275.
[8] Camidge DR，Dziadziuszko R，Peters S，et al. Effificacy and safety data and impact of the EML4-ALK Fusion variant of the effificacy of alectinib in untreated ALK-positive advan-ced Non-Small Cell Lung Cancer in the Global Phase Ⅲ ALEX Study [J]. J Thorac Oncol，2019，14（7）：1233-1243.
[9] 石远凯，孙燕，于金明，等.中国肺癌脑转移诊治专家共识（2017年版）[J].中国肺癌杂志，2017，20（1）：1-12.
[10] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline （version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247.
[11] NCI. CTCAE [EB/OL]. [2010-05-17]. http：//evs.nci.nih.gov/ftp1/CTCAE/Abou.html.
[12] Park S，Lee MH，Seong M，et al. A phase Ⅱ，multicenter，two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy [J]. Ann Oncol，2020，31（10）：1397-1404.
[13] Wakuda K，Yamaguchi H，Kenmotsu H，et al. A phase Ⅱ study of Osimertinib for patients with radiotherapy-na?觙ve CNS metastasis of non-small cell lung cancer：treatment rationale and protocol design of the OCEAN study（LOGIK 1603/WJOG 9116L）[J]. BMC Cancer，2020，20（1）：370.
[14] Liu L，Chen W，Zhang R，et al. Radiotherapy in combination with systemic therapies for brain metastases：current status and progress [J]. Cancer Biol Med，2020，17（4）：910-922.
[15] Wang J，Liu Z，Pang Q，et al. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases [J]. BMC Cancer，2020，20（1）：837.
[16] Brastianos PK，Carter SL，Santagata S，et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets [J]. Cancer Discov，2015，5（11）：1164-1177.
[17] Yamamoto M，Serizawa T，Sato Y，et al. Stereotactic radiosurgery for brain metastases：A retrospective cohort study comparing treatment results between two lung cancer patient age groups，75 years or older vs 65-74 years [J]. Lung Cancer，2020，149：103-112.
[18] Huijskens SC，Kroon PS，Gaze MN，et al. Radical radiotherapy for paediatric solid tumour metastases：An overview of current European protocols and outcomes of a SIOPE multicenter survey [J]. Eur J Cancer，2021， 145：121-131.
[19] Batumalai V，Descallar J，Delaney GP，et al. Patterns of palliative radiotherapy fractionation for brain metastases patients in New South Wales，Australia [J]. Radiother Oncol，2020，156：174-180.
[20] Brown PD，Jaeckle K，Ballman KV，et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial [J]. JAMA，2016，320（5）：510.
[21] Cho A，Untersteiner H，Hirschmann D，et al. Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy [J]. Cancers（Basel），2020，12（12）：3668.
[22] Planchard D，Popat S，Kerr K，et al. Metastatic non-small cell lung cancer：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up [J]. Ann Oncol，2018，29（Suppl 4）：iv192-iv237.
[23] Magnuson WJ，Lester-Coll NH，Wu A，et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer：A retrospective multi-institutional analysis [J]. J Clin Oncol，2017，35（10）：1070-1077.
[24] Hirsch F，Scagliotti G，Mulshine J，et al. Lung cancer：Current therapies and new targeted treatments [J]. Lancet，2017，389（10066）：299-311.
[25] Sperduto P，Yang T，Beal K，et al. Estimating survival in patients with lung cancer and brain metastases：An update of the graded prognostic assessment for lung cancer using molecular markers（Lung-molGPA）[J]. JAMA Oncol，2017，3（3）：827-831.
[26] Yomo S，Serizawa T，Yamamoto M，et al. The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery：a propensity score-matched analysis based on extended JLGK0901 dataset （JLGK0901-EGFR-TKI）[J]. J Neurooncol，2019，145（1）：151-157.
[27] Glatzer M，Faivre-Finn C，De Ruysscher D，et al. Role of radiotherapy in the management of brain metastases of NSCLC-Decision criteria in clinical routine [J]. Radiother Oncol，2020，154：269-273.
[28] Putora PM，Fischer GF，Früh M，et al. Treatment of brain metastases in small cell lung cancer：Decision-making amongst a multidisciplinary panel of European experts[J]. Radiother Oncol，2020，149：84-88.
京公网安备 11010502046598号